BioSyent Inc. (TSXV:RX)
Canada
· Delayed Price · Currency is CAD | Market Cap | 169.86M |
| Revenue (ttm) | 43.05M |
| Net Income (ttm) | 9.01M |
| Shares Out | 11.44M |
| EPS (ttm) | 0.78 |
| PE Ratio | 18.97 |
| Forward PE | 15.80 |
| Dividend | 0.22 (1.48%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 5,840 |
| Average Volume | 4,329 |
| Open | 14.75 |
| Previous Close | 14.85 |
| Day's Range | 14.50 - 14.75 |
| 52-Week Range | 10.65 - 15.80 |
| Beta | 0.65 |
| RSI | 42.97 |
| Earnings Date | May 22, 2026 |
About BioSyent
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ... [Read more]
Full Company ProfileFinancial Performance
In 2025, BioSyent's revenue was 43.05 million, an increase of 22.90% compared to the previous year's 35.03 million. Earnings were 9.01 million, an increase of 23.96%.
Financial StatementsNews
BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX), a profitable growth-stage specialty healthcare products company, is pleased to announce that it wi...
FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years
MISSISSAUGA, Ontario, April 01, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® has been named the #1 recommended over-the-counter (OTC) iron ...
BioSyent Announces Grant of Restricted Share Units
MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 44,222 Restricted Sh...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December ...
BioSyent Earnings Call Transcript: Q4 2025
Revenue grew 23% to over CAD 43 million in 2025, with net income up 24% and strong margins. The Oral Science acquisition diversifies revenue and adds a new oral health platform, while capital allocation remains focused on growth, dividends, and buybacks.
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended D...
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
MISSISSAUGA, Ontario, March 02, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) is pleased to announce that it has successfully closed the previously-announced acquisition ...
BioSyent to Acquire Oral Science Inc.
Accretive Transaction with Combined Companies' Pro-Forma Revenue in Excess of $70.00 Million and EBITDA(1) in Excess of $15.75 Million (TTM Sept 30, 2025)
BioSyent Declares First Quarter 2026 Dividend
MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...
BioSyent Releases Financial Results for Q3 and YTD 2025
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September...
BioSyent Declares Fourth Quarter 2025 Dividend
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...
BioSyent Earnings Call Transcript: Q3 2025
Record Q3 and YTD results with double-digit revenue and profit growth, strong margins, and continued cash returns to shareholders. Key brands performed well, with FeraMAX maintaining market leadership and new assets in the pipeline.
BioSyent Releases Financial Results for Q2 and H1 2025
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 20...
BioSyent Declares Third Quarter 2025 Dividend
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...
BioSyent Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 14% year-over-year to over $10 million, with strong EBITDA and NIAT margins. All business segments contributed to growth, and the company maintained a robust balance sheet, increased dividends, and continued share buybacks.
BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025
MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended Jun...
BioSyent Releases Financial Results for First Quarter 2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights ...
BioSyent Declares Second Quarter 2025 Dividend
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend o...
BioSyent Earnings Call Transcript: Q1 2025
Record Q1 2025 with revenue up 42% and EBITDA up 45% year-over-year. Net income margin reached 21%, and the company maintained a strong cash position with no debt, while continuing to invest in growth and return capital to shareholders.
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on T...
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2025 Bloom Burton & Co. Healthcar...
BioSyent Transcript: Planet MicroCap Showcase: VEGAS 2025
Strong financial performance and consistent profitability underpin a strategy focused on product innovation, disciplined capital deployment, and portfolio diversification. Recent acquisitions and launches are expected to drive future growth, with at least two new products planned.
BioSyent to Attend Planet MicroCap Showcase
MISSISSAUGA, Ontario, April 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase: VEGAS 2025 investor ...
BioSyent to Present at LD Micro New York Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 4, 2025) - BioSyent Inc. (TSXV: RX) ("BioSyent" or the "Company") announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in pe...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December ...